Last reviewed · How we verify
AL8326 high dose group
AL8326 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.
AL8326 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels. Used for Inflammatory airway disease (Phase 2 development).
At a glance
| Generic name | AL8326 high dose group |
|---|---|
| Sponsor | Advenchen Pharmaceuticals, LLC. |
| Drug class | PDE4 inhibitor |
| Target | PDE4 |
| Modality | Small molecule |
| Therapeutic area | Immunology/Respiratory |
| Phase | Phase 2 |
Mechanism of action
PDE4 inhibition leads to accumulation of cyclic adenosine monophosphate (cAMP) in immune and inflammatory cells, suppressing the release of pro-inflammatory cytokines and chemokines. This mechanism is intended to reduce inflammation in conditions driven by excessive immune activation, particularly in respiratory and inflammatory diseases.
Approved indications
- Inflammatory airway disease (Phase 2 development)
Common side effects
- Nausea
- Headache
- Diarrhea
Key clinical trials
- Phase 2 Safety and Efficacy Evaluation of AL8326 in ≥2nd Line SCLC (PHASE2)
- A Study of Diet Influence of AL8326 in Chinese Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |